Six teams have been accepted onto Phase II of the Cancer Tech Accelerator, the entrepreneur training programme from Capital Enterprise dedicated to supporting cutting-edge oncology technology commercialisation.

Selected from the 25 teams that took part in Phase I, three of the Phase II project teams will receive a £70,000 grant to continue the development of their technology, while three more Rising Stars will benefit from four months of mentorship and training.

The teams are focused on a range of new technologies, from drug discovery to diagnostics and drug delivery.

“The Phase II selection was made by an expert panel including renowned cancer researchers, tech specialists, and health and biotech investors,” said Lotus Qi, Head of MedTech at Capital Enterprise. “We congratulate all the successful teams, both those which received funding and our Rising Stars. To everyone who participated in Phase I, we look forward to welcoming them into our growing community of medtech founders.”

Siftr Bio

Siftr Bio aims to develop highly specific, low-side-effect tumour-killing drugs that are only activated when they reach solid tumours. Founded by Daniel Lucy, Archie Wall and Professor Ed Tate, the company is in the process of spinning out of Imperial College London and aims to translate 20 years of groundbreaking research into impactful therapies for patients.

Nimble Genomics

Nimble Genomics has developed an ultra-sensitive, non-invasive platform for the detection, stratification, treatment and monitoring of cancers that relies on a simple blood test. Founded by Henno Martin, a clinical oncologist with experience in cell-free DNA analysis, and Radek Lach, a researcher with experience building cfDNA tools, they are first targeting a range of brain cancers.

SynPixels

SynPixels helps radiation oncologists track changes in target tumours day by day and continually optimise radiotherapy treatment plans. Led by Ping Lin Yeap, a Gates Cambridge Scholar completing his PhD in oncology, the team’s AI-powered software as medical device (SaMD) generates daily CT-quality images in minutes, enabling daily dose evaluation and adaptation.

Senesys.Bio

Senesys.Bio’s proprietary technology enables precise detection and delivery of senolytic drugs which eliminate senescent cells, offering enhanced efficacy with reduced toxicity. The company was co-founded by three researchers from the University of Cambridge: Ioannis Prattis, Adelina Ivanova, and Ljiljana Fruk.

TileBio

TileBio leverages AI to revolutionise cancer diagnostics. Their technology automates pathology analysis, improving accuracy and enabling early detection. The founding team are Dr Christopher Walsh and Dr Ke Yuan, who lead on the computer science of self-learning AI for histopathology images, and Professors John Le Quesne and David Chang, who lead on clinical application of these methods to clinical images.

Excellio Labs

Excellio Labs pioneers breakthroughs in targeted drug delivery. They equip exosomes with tissue-specific GPS systems, optimising cargo delivery and enhancing clinical performance. Co-founded by Kasia Maj and Kamila Malysz, the team combines  Maj’s industrial experience with a focus on stem cell reprogramming and differentiation with  Malysz’s PhD in cancer epigenetics and her extensive experience in molecular biology and informatics.

Cancer Tech Accelerator is funded by Cancer Research UK with grant funding support from Cancer Research Horizons, The Brain Tumour Charity and HGF, with further support from Blood Cancer UK, LifeArc, and Roche.

Diana Spencer, Senior Digital Content Editor, DDW